AbbVie Inc Reports Positive Results from SAPPHIRE-II Study (ABBV)

On Tuesday, AbbVie Inc (ABBV) released phase III results from the SAPPHIRE-II study, which is the second of six phase 3 studies for the treatment of the hepatitis C virus (HCV) genotype 1 (GT1) infection.

AbbVie reported that in the study, which included 394 patients, 96% of those who has previously failed pegylated interferon and ribavirin treatment in the past sustained virologic response at 12 weeks with the regimen.

There are 160 million infected with hepatitis C worldwide. ABBV’s HCV program is currently the largest all oral, interferon-free clinical program in GT1 patients being conducted.

AbbVie shares were mostly flat during Tuesday morning trading. The stock is up 50% YTD.